Brief: Revive Therapeutics Announces Update On Research And Development Focus On Bucillamine
03/02/2025 22:38
Feb 3 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS ANNOUNCES UPDATE ON RESEARCH AND
DEVELOPMENT
FOCUS ON BUCILLAMINE FOR INFECTIOUS DISEASES AND MEDICAL
COUNTERMEASURES
Source text: ID:nGNXbMMl3P
Further company coverage: RVV.CD
((reuters.briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure